Novel Therapies for Acute Kidney Injury

Kidney International Reports

Volumn 2, Issue 5, 2017, Pages 785-799

  Chen, Huaizhen ^a   Busse, Laurence William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute kidney injury; angiotensin II; inflammation; intravenous fluids; oxidative stress

Indexed keywords

EID: 85030172327     PISSN: 24680249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ekir.2017.06.020     Document Type: Review

References (147)

1. Legrand, M., Dupuis, C., Simon, C., et al. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care, 17, 2013, R278.
2. Boyd, J.H., Forbes, J., Nakada, T.A., Walley, K.R., Russell, J.A., Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39 (2011), 259–265.
3. Bajwa, A., Kinsey, G.R., Okusa, M.D., Immune mechanisms and novel pharmacological therapies of acute kidney injury. Curr Drug Targets 10 (2009), 1196–1204.
4. Heemskerk, S., Masereeuw, R., Moesker, O., et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 37 (2009), 417–423 e411.
5. Pickkers, P., Heemskerk, S., Schouten, J., et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care, 16, 2012, R14.
6. Bagshaw, S.M., Ghali, W.A., Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Medicine 165 (2005), 1087–1093.
7. Dai, B., Liu, Y., Fu, L., Li, Y., Zhang, J., Mei, C., Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 60 (2012), 360–370.
8. Jo, S.-H., Kim, S.-A., Kim, H.-S., Han, S.-J., Park, W.-J., Choi, Y.J., Alpha-lipoic acid for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography: the ALIVE study - a prospective randomized trial. Cardiology 126 (2013), 159–166.
9. Ludwig, U., Riedel, M.K., Backes, M., Imhof, A., Muche, R., Keller, F., MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - controlled trial. Clin Nephrol 75 (2011), 302–308.
10. Ambrosi, N., Arrosagaray, V., Guerrieri, D., et al. Alpha-lipoic acid protects against ischemia-reperfusion injury in simultaneous kidney-pancreas transplantation. Transplantation 100 (2016), 908–915.
11. Ghorbani, A., Omidvar, B., Parsi, A., Protective effect of selenium on cisplatin induced nephrotoxicity: a double-blind controlled randomized clinical trial. J Nephropathol 2 (2013), 129–134.
12. Yoo, Y.C., Shim, J.K., Song, Y., Yang, S.Y., Kwak, Y.L., Anesthetics influence the incidence of acute kidney injury following valvular heart surgery. Kidney Int 86 (2014), 414–422.
13. Bang, J.Y., Lee, J., Oh, J., Song, J.G., Hwang, G.S., The influence of propofol and sevoflurane on acute kidney injury after colorectal surgery: a retrospective cohort study. Anesth Analg 123 (2016), 363–370.
14. Ammar, A.S., Mahmoud, K.M., Comparative effect of propofol versus sevoflurane on renal ischemia/reperfusion injury after elective open abdominal aortic aneurysm repair. Saudi J Anaesth 10 (2016), 301–307.
15. Shih, C.-J., Lee, Y.-J., Lo, Y.-H., Kuo, S.-C., Ou, S.-M., Chen, Y.-T., Association between use of dipeptidyl peptidase-4 inhibitors and the risk of acute kidney injury: a nested case-control study. Mayo Clin Proc 91 (2016), 867–872.
16. Kawasaki, I., Hiura, Y., Tamai, A., et al. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J Diabetes 7 (2015), 41–46.
17. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
18. Pendergrass, M., Fenton, C., Haffner, S.M., Chen, W., Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 14 (2012), 596–600.
19. Leite, T.T., Macedo, E., Martins Ida, S., Neves, F.M., Liborio, A.B., Renal outcomes in critically ill patients receiving propofol or midazolam. Clin J Am Soc Nephrol 10 (2015), 1937–1945.
20. Khajehdehi, P., Zanjaninejad, B., Aflaki, E., et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Renal Nutr 22 (2012), 50–57.
21. Feng, Y., Bai, T., Ma, H., Wang, J.-K., Propofol attenuates human proximal renal tubular epithelial cell injury induced by anoxia-reoxygenation. Lab Med 39 (2008), 356–360.
22. Abuelo, J.G., Normotensive ischemic acute renal failure. N Engl J Med 357 (2007), 797–805.
23. Bagshaw, S.M., George, C., Bellomo, R., Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care, 12, 2008, R47.
24. Sun, L.Y., Wijeysundera, D.N., Tait, G.A., Beattie, W.S., Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. Anesthesiology 123 (2015), 515–523.
25. Walsh, M., Devereaux, P.J., Garg, A.X., et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology 119 (2013), 507–515.
26. Schnermann, J., Concurrent activation of multiple vasoactive signaling pathways in vasoconstriction caused by tubuloglomerular feedback: a quantitative assessment. Ann Rev Physiol 77 (2015), 301–322.
27. Prowle, J.R., Bellomo, R., Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. Semin Nephrol 35 (2015), 64–74.
28. Whiting, P., Morden, A., Tomlinson, L.A., et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open, 7, 2017, e012674.
29. Schlondorff, D., Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 44 (1993), 643–653.
30. Sutton, T.A., Fisher, C.J., Molitoris, B.A., Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 62 (2002), 1539–1549.
31. Wang, Z., Holthoff, J.H., Seely, K.A., et al. Development of oxidative stress in the peritubular capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute kidney injury. Am J Pathol 180 (2012), 505–516.
32. Holthoff, J.H., Wang, Z., Seely, K.A., Gokden, N., Mayeux, P.R., Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 81 (2012), 370–378.
33. Ko, G.J., Jang, H.R., Huang, Y., et al. Blocking Fas ligand on leukocytes attenuates kidney ischemia-reperfusion injury. J Am Soc Nephrol 22 (2011), 732–742.
34. Fenhammar, J., Rundgren, M., Forestier, J., Kalman, S., Eriksson, S., Frithiof, R., Toll-like receptor 4 inhibitor TAK-242 attenuates acute kidney injury in endotoxemic sheep. Anesthesiology 114 (2011), 1130–1137.
35. Basile, D.P., Anderson, M.D., Sutton, T.A., Pathophysiology of acute kidney injury. Compr Physiol 2 (2012), 1303–1353.
36. Kashani, K., Al-Khafaji, A., Ardiles, T., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care, 17, 2013, R25.
37. Bourgoin, A., Leone, M., Delmas, A., Garnier, F., Albanese, J., Martin, C., Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 33 (2005), 780–786.
38. Poukkanen, M., Wilkman, E., Vaara, S.T., et al. Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study. Crit Care, 17, 2013, R295.
39. Payen, D., de Pont, A.C., Sakr, Y., Spies, C., Reinhart, K., Vincent, J.L., A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care, 12, 2008, R74.
40. Bouchard, J., Soroko, S.B., Chertow, G.M., et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 76 (2009), 422–427.
41. Claure-Del Granado, R., Mehta, R.L., Fluid overload in the ICU: evaluation and management. BMC Nephrol, 17, 2016, 109.
42. Grams, M.E., Estrella, M.M., Coresh, J., Brower, R.G., Liu, K.D., Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 6 (2011), 966–973.
43. Wang, N., Jiang, L., Zhu, B., Wen, Y., Xi, X.M., Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study. Crit Care, 19, 2015, 371.
44. Perner, A., Haase, N., Guttormsen, A.B., et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 367 (2012), 124–134.
45. Myburgh, J.A., Finfer, S., Bellomo, R., et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367 (2012), 1901–1911.
46. Zarychanski, R., Abou-Setta, A.M., Turgeon, A.F., et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309 (2013), 678–688.
47. Rackow, E.C., Falk, J.L., Fein, I.A., et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 11 (1983), 839–850.
48. Wiedermann, C.J., Dunzendorfer, S., Gaioni, L.U., Zaraca, F., Joannidis, M., Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care, 14, 2010, R191.
49. Caironi, P., Tognoni, G., Masson, S., et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370 (2014), 1412–1421.
50. Finfer, S., Bellomo, R., Boyce, N., French, J., Myburgh, J., Norton, R., A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 (2004), 2247–2256.
51. Wilcox, C.S., Regulation of renal blood flow by plasma chloride. J Clin Investig 71 (1983), 726–735.
52. Yunos, N.M., Bellomo, R., Glassford, N., Sutcliffe, H., Lam, Q., Bailey, M., Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis. Intens Care Med 41 (2015), 257–264.
53. Yunos, N.M., Bellomo, R., Hegarty, C., Story, D., Ho, L., Bailey, M., Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308 (2012), 1566–1572.
54. Young, P., Bailey, M., Beasley, R., et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial. JAMA 314 (2015), 1701–1710.
55. Prowle, J.R., Echeverri, J.E., Ligabo, E.V., Ronco, C., Bellomo, R., Fluid balance and acute kidney injury. Nature Rev Nephrol 6 (2010), 107–115.
56. Chawla, L.S., Busse, L., Brasha-Mitchell, E., et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care, 18, 2014, 534.
57. Correa, T.D., Takala, J., Jakob, S.M., Angiotensin II in septic shock. Crit Care, 19, 2015, 98.
58. Brown, N.J., Vaughan, D.E., Angiotensin-converting enzyme inhibitors. Circulation 97 (1998), 1411–1420.
59. Rosa, R.M., Colucci, J.A., Yokota, R., et al. Alternative pathways for angiotensin II production as an important determinant of kidney damage in endotoxemia. Am J Physiol Renal Physiol 311 (2016), F496–F504.
60. Bucher, M., Ittner, K.P., Hobbhahn, J., Taeger, K., Kurtz, A., Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension (Dallas, Tex: 1979) 38 (2001), 177–182.
61. Correa, T.D., Jeger, V., Pereira, A.J., Takala, J., Djafarzadeh, S., Jakob, S.M., Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med 42 (2014), e550–e559.
62. Wan, L., Langenberg, C., Bellomo, R., May, C.N., Angiotensin II in experimental hyperdynamic sepsis. Crit Care, 13, 2009, R190.
63. May, C.N., Ishikawa, K., Wan, L., et al. Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion. Intens Care Med 38 (2012), 886–893.
64. Khanna, A., English, S.W., Wang, X.S., et al. Angiotensin II for the treatment of vasodilatory shock. [e-pub ahead of print] N Engl J Med, 2017, 10.1056/NEJMoa1704154.
65. Vallon, V., Muhlbauer, B., Osswald, H., Adenosine and kidney function. Physiol Rev 86 (2006), 901–940.
66. Day, Y.J., Huang, L., McDuffie, M.J., et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112 (2003), 883–891.
67. Okusa, M.D., Linden, J., Macdonald, T., Huang, L., Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 277:3 Pt 2 (1999), F404–F412.
68. Axelrod, D.M., Sutherland, S.M., Anglemyer, A., Grimm, P.C., Roth, S.J., A double-blinded, randomized, placebo-controlled clinical trial of aminophylline to prevent acute kidney injury in children following congenital heart surgery with cardiopulmonary bypass. Pediatr Crit Care M 17 (2016), 135–143.
69. Voors, A.A., Dittrich, H.C., Massie, B.M., et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol 57 (2011), 1899–1907.
70. Devarajan, P., Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17 (2006), 1503–1520.
71. Lee, S.R., Jeong, M.H., Lim, S.Y., et al. The effect of alpha lipoic acid (Thioctacid HR®) on endothelial function in diabetic and hypertensive patients. Korean Circ J 36 (2006), 559–564.
72. Kang, K.P., Kim, D.H., Jung, Y.J., et al. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 24 (2009), 3012–3020.
73. Melhem, M.F., Craven, P.A., Derubertis, F.R., Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol 12 (2001), 124–133.
74. Briguori, C., Visconti, G., Rivera, N.V., et al. Cystatin C and contrast-induced acute kidney injury. Circulation 121 (2010), 2117–2122.
75. Haase, M., Bellomo, R., Devarajan, P., Schlattmann, P., Haase-Fielitz, A., Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54 (2009), 1012–1024.
76. Malyszko, J., Bachorzewska-Gajewska, H., Poniatowski, B., Malyszko, J.S., Dobrzycki, S., Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Renal Fail 31 (2009), 910–919.
77. Cicek, M., Yıldırır, A., Okyay, K., et al. Use of alpha-lipoic acid in prevention of contrast-induced nephropathy in diabetic patients. Renal Failure 35 (2013), 748–753.
78. Takaoka, M., Ohkita, M., Kobayashi, Y., Yuba, M., Matsumura, Y., Protective effect of alpha-lipoic acid against ischaemic acute renal failure in rats. Clin Exp Pharmacol Physiol 29 (2002), 189–194.
79. Li, G., Gao, L., Jia, J., Gong, X., Zang, B., Chen, W., Alpha-Lipoic acid prolongs survival and attenuates acute kidney injury in a rat model of sepsis. Clin Exp Pharmacol Physiol 41 (2014), 459–468.
80. Abdel-Zaher, A.O., Abdel-Hady, R.H., Mahmoud, M.M., Farrag, M.M.Y., The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology 243 (2008), 261–270.
81. Wongmekiat, O., Leelarungrayub, D., Thamprasert, K., Alpha-lipoic acid attenuates renal injury in rats with obstructive nephropathy. Biomed Res Int, 2013, 2013, 138719.
82. Aksoy, A., Karaoglu, A., Akpolat, N., Naziroglu, M., Ozturk, T., Karagoz, Z.K., Protective role of selenium and high dose vitamin E against cisplatin-induced nephrotoxicty in rats. Asian Pac J Cancer Prev 16 (2015), 6877–6882.
83. Iglesias, P., Selgas, R., Romero, S., Diez, J.J., Selenium and kidney disease. J Nephrol 26 (2013), 266–272.
84. Randjelovic, P., Veljkovic, S., Stojiljkovic, N., et al. Protective effect of selenium on gentamicin-induced oxidative stress and nephrotoxicity in rats. Drug Chem Toxicol 35 (2012), 141–148.
85. Liu, L., Liu, C., Hou, L., et al. Protection against ischemia/reperfusioninduced renal injury by cotreatment with erythropoietin and sodium selenite. Mol Med Rep 12 (2015), 7933–7940.
86. Treska, V., Kuntscher, V., Hasman, D., et al. Importance of selenium for the influence of ischemia-reperfusion syndrome after kidney transplantation from a non-heart beating donor in a pig model. Transplant Proc 34 (2002), 3057–3059.
87. Hu, Y.J., Chen, Y., Zhang, Y.Q., et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Element Res 56 (1997), 331–341.
88. Weijl, N.I., Elsendoorn, T.J., Lentjes, E.G., et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40 (2004), 1713–1723.
89. El-Nahas, A.R., Elsaadany, M.M., Taha, D.E., et al. A randomised controlled trial evaluating renal protective effects of selenium with vitamins A, C, E, verapamil, and losartan against extracorporeal shockwave lithotripsy-induced renal injury. BJU Int 119 (2017), 142–147.
90. Berger, M.M., Soguel, L., Shenkin, A., et al. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. Crit Care, 12, 2008, R101.
91. Stoppe, C., McDonald, B., Rex, S., et al. SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients. Trials, 15, 2014, 339.
92. Mashiach, E., Sela, S., Weinstein, T., Cohen, H.I., Shasha, S.M., Kristal, B., Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure. Nephrol Dial Transplant 16 (2001), 542–551.
93. Dechant, K.L., Brogden, R.N., Pilkington, T., Faulds, D., Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42 (1991), 428–467.
94. Schoenike, S.E., Dana, W.J., Ifosfamide and mesna. Clin Pharm 9 (1990), 179–191.
95. Skinner, R., Sharkey, I.M., Pearson, A.D., Craft, A.W., Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11 (1993), 173–190.
96. Murphy, P.G., Myers, D.S., Davies, M.J., Webster, N.R., Jones, J.G., The antioxidant potential of propofol (2,6-diisopropylphenol). Br J Anaesth 68 (1992), 613–618.
97. Rodriguez-Lopez, J.M., Sanchez-Conde, P., Lozano, F.S., et al. Laboratory investigation: effects of propofol on the systemic inflammatory response during aortic surgery. Can J Anaesth 53 (2006), 701–710.
98. Sánchez-Conde, P., Rodríguez-López, J.M., Nicolás, J.L., et al. The comparative abilities of propofol and sevoflurane to modulate inflammation and oxidative stress in the kidney after aortic cross-clamping. Anesth Analg 106 (2008), 371–378.
99. Wang, H.H., Zhou, H.Y., Chen, C.C., Zhang, X.L., Cheng, G., Propofol attenuation of renal ischemia/reperfusion injury involves heme oxygenase-1. Acta Pharmacol Sin 28 (2007), 1175–1180.
100. Topcu-Tarladacalisir, Y., Sapmaz-Metin, M., Karaca, T., Curcumin counteracts cisplatin-induced nephrotoxicity by preventing renal tubular cell apoptosis. Ren Fail 38 (2016), 1741–1748.
101. He, L., Peng, X., Zhu, J., et al. Protective effects of curcumin on acute gentamicin-induced nephrotoxicity in rats. Can J Physiol Pharmacol 93 (2015), 275–282.
102. Chen, H.W., Kuo, H.T., Chai, C.Y., Ou, J.L., Yang, R.C., Pretreatment of curcumin attenuates coagulopathy and renal injury in LPS-induced endotoxemia. J Endotoxin Res 13 (2007), 15–23.
103. Aydin, M.S., Caliskan, A., Kocarslan, A., et al. Intraperitoneal curcumin decreased lung, renal and heart injury in abdominal aorta ischemia/reperfusion model in rat. Int J Surg (London) 12 (2014), 601–605.
104. Chen, T.H., Yang, Y.C., Wang, J.C., Wang, J.J., Curcumin treatment protects against renal ischemia and reperfusion injury-induced cardiac dysfunction and myocardial injury. Transplant Proc 45 (2013), 3546–3549.
105. Hammad, F.T., Al-Salam, S., Lubbad, L., Curcumin provides incomplete protection of the kidney in ischemia reperfusion injury. Physiol Res 61 (2012), 503–511.
106. Awad, A.S., El-Sharif, A.A., Curcumin immune-mediated and anti-apoptotic mechanisms protect against renal ischemia/reperfusion and distant organ induced injuries. Int Immunopharmacol 11 (2011), 992–996.
107. Bayrak, O., Uz, E., Bayrak, R., et al. Curcumin protects against ischemia/reperfusion injury in rat kidneys. World J Urol 26 (2008), 285–291.
108. Vlahovic, P., Cvetkovic, T., Savic, V., Stefanovic, V., Dietary curcumin does not protect kidney in glycerol-induced acute renal failure. Food Chem Toxicol 45 (2007), 1777–1782.
109. Sood, A., Mathew, R., Trachtman, H., Cytoprotective effect of curcumin in human proximal tubule epithelial cells exposed to shiga toxin. Biochem Biophys Res Commun 283 (2001), 36–41.
110. Yang, H., Xu, W., Zhou, Z., et al. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp Clin Endocrinol Diabetes 123 (2015), 360–367.
111. Suresh Babu, P., Srinivasan, K., Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 181 (1998), 87–96.
112. Srinivasan, M., Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26 (1972), 269–270.
113. Cohen, J., The immunopathogenesis of sepsis. Nature 420 (2002), 885–891.
114. Peters, E., Heemskerk, S., Masereeuw, R., Pickkers, P., Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients. Am J Kidney Dis 63 (2014), 1038–1048.
115. Kalakeche, R., Hato, T., Rhodes, G., et al. Endotoxin uptake by S1 proximal tubular segment causes oxidative stress in the downstream S2 segment. J Am Soc Nephrol 22 (2011), 1505–1516.
116. Zarjou, A., Agarwal, A., Sepsis and acute kidney injury. J Am Soc Nephrol 22 (2011), 999–1006.
117. Wu, L., Tiwari, M.M., Messer, K.J., et al. Peritubular capillary dysfunction and renal tubular epithelial cell stress following lipopolysaccharide administration in mice. Am J Physiol Renal Physiol 292 (2007), F261–F268.
118. Roberts, V., Lu, B., Rajakumar, S., Cowan, P.J., Dwyer, K.M., The CD39-adenosinergic axis in the pathogenesis of renal ischemia–reperfusion injury. Puriner Signal 9 (2013), 135–143.
119. Lee, H.T., Emala, C.W., Adenosine attenuates oxidant injury in human proximal tubular cells via A(1) and A(2a) adenosine receptors. Am J Physiol Renal Physiol 282 (2002), F844–F852.
120. Peters, E., Mehta, R.L., Murray, P.T., et al. Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI). BMJ Open, 6, 2016, e012371.
121. Lee, Y.S., Jun, H.S., Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediat Inflamm, 2016, 2016, 3094642.
122. Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., Oka, J.-I., Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res 55 (2006), 352–360.
123. Blandino-Rosano, M., Perez-Arana, G., Mellado-Gil, J.M., Segundo, C., Aguilar-Diosdado, M., Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J Mol Endocrinol 41 (2008), 35–44.
124. Liu, H., Dear, A.E., Knudsen, L.B., Simpson, R.W., A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201 (2009), 59–66.
125. Fujita, H., Morii, T., Fujishima, H., et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85 (2014), 579–589.
126. Crajoinas, R.O., Oricchio, F.T., Pessoa, T.D., et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301 (2011), F355–F363.
127. Schlatter, P., Beglinger, C., Drewe, J., Gutmann, H., Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regulatory Peptides 141 (2007), 120–128.
128. Kodera, R., Shikata, K., Takatsuka, T., et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 443 (2014), 828–833.
129. Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C., Panchapakesan, U., Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. Nephrology (Carlton, Vic) 21 (2016), 423–431.
130. Nakashima, S., Matsui, T., Takeuchi, M., Yamagishi, S.I., Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Hormone Metab Res 46 (2014), 717–721.
131. Marques, C., Mega, C., Goncalves, A., et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm, 2014, 2014, 538737.
132. Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., Nangaku, M., Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol 308 (2015), F878–F887.
133. Katagiri, D., Hamasaki, Y., Doi, K., et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24 (2013), 2034–2043.
134. Chen, Y.T., Tsai, T.H., Yang, C.C., et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med, 11, 2013, 270.
135. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
136. Cornel, J.H., Bakris, G.L., Stevens, S.R., et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 39 (2016), 2304–2310.
137. Bajwa, A., Rosin, D.L., Chroscicki, P., et al. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol 26 (2015), 908–925.
138. Awad, A.S., Ye, H., Huang, L., et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 290 (2006), F1516–F1524.
139. Lien, Y.H., Yong, K.C., Cho, C., Igarashi, S., Lai, L.W., S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 69 (2006), 1601–1608.
140. Budde, K., Schutz, M., Glander, P., et al. FTY720 (fingolimod) in renal transplantation. Clin Transpl 20 Suppl 17 (2006), 17–24.
141. Yang, Q.H., Liu, D.W., Long, Y., Liu, H.Z., Chai, W.Z., Wang, X.T., Acute renal failure during sepsis: potential role of cell cycle regulation. J Infection 58 (2009), 459–464.
142. Rodier, F., Campisi, J., Bhaumik, D., Two faces of p53: aging and tumor suppression. Nucleic Acids Res 35 (2007), 7475–7484.
143. Thompson, J.D., Kornbrust, D.J., Foy, J.W., et al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther 22 (2012), 255–264.
144. Powell JT, Tsapepas DS, Martin ST, Hardy MA, Ratner LE. Managing renal transplant ischemia reperfusion injury: novel therapies in the pipeline. Clin Transpl.27:484–491.
145. Molitoris, B.A., Dagher, P.C., Sandoval, R.M., et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 20 (2009), 1754–1764.
146. Fujino, T., Muhib, S., Sato, N., Hasebe, N., Silencing of p53 RNA through transarterial delivery ameliorates renal tubular injury and downregulates GSK-3beta expression after ischemia-reperfusion injury. Am J Physiol Renal Physiol 305 (2013), F1617–F1627.
147. Glebova, K., Reznik, O.N., Reznik, A.O., et al. siRNA technology in kidney transplantation: current status and future potential. BioDrugs 28 (2014), 345–361.